AI reads heart tracings to help identify hypertrophic cardiomyopathy types
Tests AI reading ECG heart tracings to classify hypertrophic cardiomyopathy in adults.
Plain-language title generated from the registry record
Registry title: AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy
Key facts
- Where
- Hangzhou, ChinaSee the site
Where in China
- Second Affiliated Hospital, Zhejiang University School of MedicineHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Trial code
- NCT07263204
- Record updated
- 4 December 2025
- Original description
By harnessing artificial intelligence to decode the 12-lead electrocardiogram, the project will enable precise ECG-based phenotyping of hypertrophic cardiomyopathy-accurately classifying septal, apical, and other morphologic subtypes-while simultaneously differentiating HCM from hypertensive heart disease, aortic stenosis, and other phenocopy disorders.Read full original descriptionShow less
Precision Diagnosis and Prognostic Prediction of Hypertrophic Cardiomyopathy Using Artificial Intelligence: A Multicenter Study
By harnessing artificial intelligence to decode the 12-lead electrocardiogram, the project will enable precise ECG-based phenotyping of hypertrophic cardiomyopathy-accurately classifying septal, apical, and other morphologic subtypes-while simultaneously differentiating HCM from hypertensive heart disease, aortic stenosis, and other phenocopy disorders.
Inclusion: Adults aged ≥ 18 years; HCM cohort: Adults diagnosed with hypertrophic cardiomyopathy in accordance with the *2023 Chinese Guidelines for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy in Adults*; HCM phenocopy cohort: Adults with an LV wall thickness ≥ 13 mm at any site on echocardiography; Healthy-control cohort: Adults with no history of cardiac disease and no evidence of myocardial hypertrophy on echocardiography.
Exclusion: Patients from whom analyzable ECG data cannot be obtained.